Cargando…

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

BACKGROUND: The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better discrimination for overall survival (OS) at diagnosis is needed. We address this issue by developing and validating a prognostic nomogram and a score for OS in LAPC (PROLAP). METHODS: Analy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vernerey, Dewi, Huguet, Florence, Vienot, Angélique, Goldstein, David, Paget-Bailly, Sophie, Van Laethem, Jean-Luc, Glimelius, Bengt, Artru, Pascal, Moore, Malcolm J, André, Thierry, Mineur, Laurent, Chibaudel, Benoist, Benetkiewicz, Magdalena, Louvet, Christophe, Hammel, Pascal, Bonnetain, Franck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2016
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4973163/ https://www.ncbi.nlm.nih.gov/pubmed/27404456 http://dx.doi.org/10.1038/bjc.2016.212

Ejemplares similares

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
por: Bachet, Jean-Baptiste, et al.
Publicado: (2015)

Erratum to: Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty
por: Vernerey, Dewi, et al.
Publicado: (2016)

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty
por: Vernerey, Dewi, et al.
Publicado: (2016)

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
por: Anota, Amélie, et al.
Publicado: (2013)

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2015)

NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial)
por: Brouquet, Antoine, et al.
Publicado: (2020)

Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
por: Charton, Emilie, et al.
Publicado: (2019)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2016)

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial
por: Hamidou, Zeinab, et al.
Publicado: (2016)

Health-related quality of life assessment for patients with advanced or metastatic renal cell carcinoma treated with a tyrosine kinase inhibitor using electronic patient-reported outcomes in daily clinical practice (QUANARIE trial): study protocol
por: Mouillet, Guillaume, et al.
Publicado: (2019)

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial
por: Anota, Amélie, et al.
Publicado: (2015)

Anti-Telomerase CD4(+) Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials
por: Spehner, Laurie, et al.
Publicado: (2020)

Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial
por: Neuzillet, Cindy, et al.
Publicado: (2015)

Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study
por: Diouf, Momar, et al.
Publicado: (2014)

Interest of the Addition of Taxanes to Standard Treatment in First-Line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients
por: Orillard, Emeline, et al.
Publicado: (2022)

Additive Value of Preoperative Sarcopenia and Lymphopenia for Prognosis Prediction in Localized Pancreatic Ductal Adenocarcinoma
por: d’Engremont, Christelle, et al.
Publicado: (2021)

Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study
por: Chibaudel, Benoist, et al.
Publicado: (2015)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
por: Cohen, Romain, et al.
Publicado: (2020)

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO – PRODIGE 82)
por: Vienot, Angélique, et al.
Publicado: (2023)

Cholangiocarcinoma: the quest for a second-line systemic treatment
por: Vienot, Angélique, et al.
Publicado: (2019)

Prognostic nomogram for previously untreated adult patients with acute myeloid leukemia
por: Zheng, Zhuojun, et al.
Publicado: (2016)

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study
por: Jacquinot, Quentin, et al.
Publicado: (2017)

HPV16 Load Is a Potential Biomarker to Predict Risk of High-Grade Cervical Lesions in High-Risk HPV-Infected Women: A Large Longitudinal French Hospital-Based Cohort Study
por: Baumann, Antoine, et al.
Publicado: (2021)

Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review
por: Fiteni, Frédéric, et al.
Publicado: (2014)

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
por: Kim, Stefano, et al.
Publicado: (2022)

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
por: Carola, Candice, et al.
Publicado: (2018)

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial
por: Auclin, Edouard, et al.
Publicado: (2019)

FOLFOXIRI vs FOLFIRINOX as first-line chemotherapy in patients with advanced pancreatic cancer: A population-based cohort study
por: Vienot, Angélique, et al.
Publicado: (2020)

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study
por: Lucidarme, Olivier, et al.
Publicado: (2019)

Immune Therapy for Liver Cancers
por: Hilmi, Marc, et al.
Publicado: (2019)

The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas
por: Kim, Stefano, et al.
Publicado: (2015)

DCF versus doublet chemotherapy as first-line treatment of advanced squamous anal cell carcinoma: a multicenter propensity score-matching study
por: Kim, Stefano, et al.
Publicado: (2023)

Multidisciplinary treatment of patients with rectal cancer: Development during the past decades and plans for the future
por: Glimelius, Bengt
Publicado: (2012)

Optimal Time Intervals between Pre-Operative Radiotherapy or Chemoradiotherapy and Surgery in Rectal Cancer?
por: Glimelius, Bengt
Publicado: (2014)

On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery
por: Glimelius, Bengt
Publicado: (2017)

A Phase II Study Evaluating the Interest to Combine UCPVax, a Telomerase CD4 T(H)1-Inducer Cancer Vaccine, and Atezolizumab for the Treatment of HPV Positive Cancers: VolATIL Study
por: Rebucci-Peixoto, Magali, et al.
Publicado: (2022)

A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy
por: Duan, Jingjing, et al.
Publicado: (2018)

Adjuvant Chemotherapy in Elderly Colorectal Cancer Patients
por: Glimelius, Bengt, et al.
Publicado: (2020)

ASO Author Reflections: Emerging Risk Factors in Colon Cancer—End of the Line for Clinomics?
por: Osterman, Erik, et al.
Publicado: (2019)

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment
por: Pastor, Brice, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_s44qlf5vjqpqr1k2hunmka45kg